ICML 2011

 
 
 

11th International Conference on Malignant Lymphoma

 

Experts face off on issues in FL

Erilyn Riley Read Article
Published: 06/30/11

Kimby_Eva_MD, PhD_11-ICML.jpg
Eva Kimby, MD, PhD

The world of follicular lymphoma (FL) has changed dramatically in the last 5 years and treatment paradigms are in a state of flux. Four experts faced off recently on issues regarding first-line treatment and maintenance therapy in follicular lymphoma at the 11th International Conference on Malignant Lymphoma. 11-ICML was held June 15-18 in Lugano, Switzerland. [Read Article]

KW-0761 continues to show antitumor activity in ATL

Erilyn Riley Read Article
Published: 06/29/11

Tobinai_Kensei_MD, PhD_11-ICML.jpg
Kensei Tobinai, MD, PhD

The anti-CCR4 antibody KW-0761 continues to have encouraging efficacy in patients with adult T-cell leukemia-lymphoma (ATL), as demonstrated by the results of a phase 2 trial in relapsed CCR4-positive patients. Kensei Tobinai, MD, PhD, of the National Cancer Center Hospital in Tokyo, Japan, reported a 50% overall response rate and other promising data at the 11th International Conference on Malignant Lymphoma held recently in Lugano, Switzerland. [Read Article]

PCI-32765 interim results favorable in poor-risk CLL

Erilyn Riley Read Article
Published: 06/28/11

O'Brien_Susan_11-ICML.jpg
Susan O'Brien, MD

Interim results of a phase 1b/2 study of the Btk inhibitor PCI-32765 in poor-risk chronic lymphocytic leukemia (CLL) patients were reported recently at the 11th International Conference on Malignant Lymphoma. Susan O'Brien, MD, of MD Anderson Cancer Center in Houston, Texas, related that the number of complete responses has doubled in the last 6 months since ASH. [Read Article]

Indolent B-cell NHL patients benefit from inotuzumab

Erilyn Riley Read Article
Published: 06/27/11

Encouraged by results of the antibody-drug conjugate inotuzumab ozogamicin in aggressive non-Hodgkin lymphoma (NHL), investigators undertook a phase 2 study of the agent in CD22-positive indolent B-cell NHL. André Goy, MD, of the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey, reported that the agent has achieved to date a 67% response rate in follicular lymphoma with 31% achieving a complete response. He reported the results at the 11th International Conference on Malignant Lymphoma. [Read Article]

New treatment on the horizon for ALCL

Erilyn Riley Read Article
Published: 06/24/11

Shustov_Andrei R_11-ICML photos 659_Shustov.jpg
Andrei R. Shustov, MD

Few therapies are available to treat systemic anaplastic large-cell lymphoma (sALCL), but one is looming on the horizon with an 86% overall response rate in relapsed or refractory patients. Andrei R. Shustov, MD, of the University of Washington in Seattle, presented updated results of the phase 2 study of brentuximab vedotin (SGN-35) at the 11th International Conference on Malignant Lymphoma held June 15 - 18 in Lugano, Switzerland. [Read Article]

Blinatumomab active in both indolent and aggressive NHL

Erilyn Riley Read Article
Published: 06/23/11

Bargou_Ralf C._MD_11-ICML.jpg
Ralf C. Bargou, MD

Based on the earlier success of blinatumomab in acute lymphoblastic leukemia, investigators undertook a phase 1 trial of the bispecific T-cell engager CD19/CD3 antibody in relapsed non-Hodgkin lymphoma (NHL). Ralf C. Bargou, MD, from the University Hospital in Würzburg, Germany, reported updated results of the ongoing trial at the 11th International Conference on Malignant Lymphoma held recently in Lugano, Switzerland. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}